SCHEMBL4391457

SCHEMBL4391457

O=c1c(OC2O[C@H](CO)[C@@H](O)[C@H](O)[C@H]2O)c(-c2ccc(O)cc2)oc2cc(OC3O[C@H](CO)[C@@H](O)[C@H](O)[C@H]3O)cc(O)c12

nearest known ligand 0.87

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ P4HB P07237 4/20 0.87
▸ AKR1B1 P15121 4/20 0.87
▸ CA12 O43570 2/20 0.87
▸ CA2 P00918 2/20 0.87
▸ CA4 P22748 2/20 0.87
▸ CA7 P43166 2/20 0.87
▸ ACHE P22303 1/20 0.87
▸ KDM4E B2RXH2 4/20 0.76
▸ GAA P10253 4/20 0.76
▸ POLB P06746 3/20 0.76
▸ APEX1 P27695 1/20 0.76
▸ RECQL P46063 1/20 0.76
▸ EPHX2 P34913 5/20 0.75
▸ SMN1; SMN2 Q16637 3/20 0.75
▸ MAPT P10636 2/20 0.75
▸ SLCO2B1 O94956 2/20 0.75
▸ LMNA P02545 2/20 0.75
▸ ADRA2C P18825 1/20 0.75
▸ NOX4 Q9NPH5 1/20 0.75
▸ KDM1A O60341 1/20 0.75

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30217565 1.00 P4HB (0.87) P4HBAKR1B1CA12CA2CA4
SCHEMBL27193647 1.00 P4HB (0.87) P4HBAKR1B1CA12CA2CA4
SCHEMBL9993788 1.00 P4HB (0.87) P4HBAKR1B1CA12CA2CA4
SCHEMBL29453024 1.00 P4HB (0.87) P4HBAKR1B1CA12CA2CA4
SCHEMBL31173775 1.00 P4HB (0.87) P4HBAKR1B1CA12CA2CA4
SCHEMBL30456667 0.95 P4HB (0.79) P4HBAKR1B1CA12CA2CA4
SCHEMBL9993267 0.95 P4HB (0.79) P4HBAKR1B1CA12CA2CA4
SCHEMBL30217549 0.95 P4HB (0.79) P4HBAKR1B1CA12CA2CA4
SCHEMBL30637576 0.95 P4HB (0.79) P4HBAKR1B1CA12CA2CA4
SCHEMBL31720497 0.95 P4HB (0.79) P4HBAKR1B1CA12CA2CA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4257188-A1 DERMATOLOGICALLY ACTIVE COMPOSITION COMPRISING CATECHINS AND FLAVONOIDS BioActive Food GmbH (DE) 2023-10-11 — — EP disclosed
EP-3142671-B1 COMBINATION OF BIOLOGICALLY ACTIVE SUBSTANCES FOR TREATING HYPERGLYCEMIC DISEASES BIOACTIVE FOOD GMBH (DE) 2021-12-22 — — EP disclosed
US-10358426-B2 Fungicidal substituted 2-[2-halogenalkyl-4-(phenoxy)-phenyl]-1-[1,2,4]triazol-1-yl-ethanol compounds BASF Agro B.V. (NL) 2019-07-23 — — US disclosed
US-20170081296-A1 Fungicidal substituted 2-[2-halogenalkyl-4-(phenoxy)-phenyl]-1-[1,2,4]triazol-1-yl-ethanol compounds BASF AGRO BV (NL) 2017-03-23 — — US disclosed
EP-2944311-A1 Combination of biologically active substances for treating hyperglycemic diseases BioActive Food GmbH (DE) 2015-11-18 — — EP disclosed
EP-2130544-A2 Processes for obtaining lignan extracts and compositions containing the lignan extracts Archer-Daniels-Midland Company (US) 2009-12-09 — — EP disclosed
US-20070141178-A1 Processes for Obtaining Lignan Extracts and Compositions Containing the Lignan Extracts ARCHER DANIELS MIDLAND COMPANY 2007-06-21 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170081296-A1 Fungicidal substituted 2-[2-halogenalkyl-4-(phenoxy)-phenyl]-1-[1,2,4]triazol-1-yl-ethanol compounds CYP2E1, TH, CYP1A1 P4HB 3861/4885AKR1B1 1029/4885CA12 4465/4885
US-10358426-B2 Fungicidal substituted 2-[2-halogenalkyl-4-(phenoxy)-phenyl]-1-[1,2,4]triazol-1-yl-ethanol compounds CYP2E1, TH, CYP1A1 P4HB 3861/4885AKR1B1 1029/4885CA12 4465/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback